Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer-Reference-Cited by-同舟云学术

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Published:2018-06-14 Issue:1 Volume:20 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Norton Nadine,Fox Nicholas,McCarl Christie-Ann,Tenner Kathleen S.,Ballman Karla,Erskine Courtney L.,Necela Brian M.,Northfelt Donald,Tan Winston W.,Calfa Carmen,Pegram Mark,Colon-Otero Gerardo,Perez Edith A.,Clynes Raphael,Knutson Keith L.

Funder

Dana Foundation

Susan G. Komen

26.2 with Donna Doundation

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-018-0989-8.pdf

Reference26 articles.

1. Gyawali B, Niraula S. Duration of adjuvant trastuzumab in HER2 positive breast cancer: overall and disease free survival results from meta-analyses of randomized controlled trials. Cancer Treat Rev. 2017;60:18–23.

2. Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012;1042:159–62.

3. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;2645:6469–87.

4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 2001;34411:783–92.

5. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;3233:3744–52.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictability of B cell clonal persistence and immunosurveillance in breast cancer;Nature Immunology;2024-05

2. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016);Journal for ImmunoTherapy of Cancer;2023-11

3. Host genetic background regulates the capacity for anti-tumor antibody-dependent phagocytosis;2023-05-09

4. Resistance to Trastuzumab;Cancers;2022-10-19

5. Role of Fcγ receptors in HER2-targeted breast cancer therapy;Journal for ImmunoTherapy of Cancer;2022-01